Pancreatic Cancer Research

ResearcherShanghai Jiao Tong UniversityActive in the last 2 years

Xiaxing Deng

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1565-4229; OpenAlex author ID A5101518549. Sources: OpenAlex.

Their work

Papers
50 (first author 2, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
93
Papers, trials and grants by year

2013: 1 paper · 2014: 2 papers · 2015: 2 papers · 2016: 2 papers · 2017: 1 paper · 2018: 1 paper · 2019: 6 papers · 2020: 4 papers · 2021: 10 papers · 2022: 7 papers · 2023: 9 papers · 2024: 4 papers · 2025: none · 2026: 1 paper

Papers 50

  1. Nimotuzumab Plus Gemcitabine-based Adjuvant Chemotherapy for Resectable Pancreatic Cancer: A Retrospective Observational Study. Co-author DOI 10.1097/mpa.0000000000002511↗
  2. The inverted U-shaped relationship between epinephrine and pancreatic ductal adenocarcinoma patients' survival with compensation of lymphocyte. Last author DOI 10.1002/cam4.7164↗
  3. ATF3-induced activation of NF-κB pathway results in acquired PARP inhibitor resistance in pancreatic adenocarcinoma. Co-author DOI 10.1007/s13402-023-00907-5↗
  4. Driver mutation subtypes involve with differentiated immunophenotypes influencing pancreatic cancer outcomes. Co-author DOI 10.1016/j.canlet.2024.217134↗
  5. Prospective observational study on biomarkers of response in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41591-023-02790-x↗
  6. Real-world implications of nonbiological factors with staging, clinical management, and prognostic prediction in pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/cam4.4910↗
  7. Risk factors for and prognostic values of postoperative acute kidney injury after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: A retrospective… Co-author DOI 10.1002/cam4.5543↗
  8. Pancreatic index: A prognostic factor of upfront surgery for body or tail pancreatic ductal adenocarcinoma with vascular involvement-A retrospective study. Co-author DOI 10.1002/cam4.6687↗
  9. Long-term outcomes of standard versus extended lymphadenectomy in pancreatoduodenectomy for pancreatic ductal adenocarcinoma: A Chinese multi-center prospectiv… Co-author DOI 10.1016/j.jare.2022.09.011↗
  10. Schwann cells regulate tumor cells and cancer-associated fibroblasts in the pancreatic ductal adenocarcinoma microenvironment. Co-author DOI 10.1038/s41467-023-40314-w↗
  11. Specific human leukocyte antigen class I genotypes predict prognosis in resected pancreatic adenocarcinoma: a retrospective cohort study. Co-author DOI 10.1097/js9.0000000000000264↗
  12. TP53 missense mutation reveals gain-of-function properties in small-sized KRAS transformed pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12967-023-04742-y↗
  13. The Impact of Additional Para-aortic Dissection During Pancreaticoduodenectomy for Resectable Pancreatic Cancer. Co-author DOI 10.1245/s10434-022-12700-z↗
  14. Comprehensive machine learning-generated classifier identifies pro-metastatic characteristics and predicts individual treatment in pancreatic cancer: A multice… Co-author DOI 10.7150/thno.84978↗
  15. The impact of Omicron pandemic and COVID-19 vaccination on the pancreatic adenocarcinoma patients. Co-author DOI 10.1002/aac2.12056↗
  16. Who could complete and benefit from the adjuvant chemotherapy regarding pancreatic ductal adenocarcinoma? A multivariate-adjusted analysis at the pre-adjuvant … Co-author DOI 10.1002/cam4.4698↗
  17. Robotic versus open pancreaticoduodenectomy with vascular resection for pancreatic ductal adenocarcinoma: surgical and oncological outcomes from pilot experien… Co-author DOI 10.1007/s00423-021-02364-w↗
  18. Clinical characteristics and surgical outcomes of resectable acinar cell carcinoma of the pancreas-propensity score matching analysis with pancreatic ductal ad… Co-author DOI 10.1016/j.ejso.2021.11.135↗
  19. Oncological outcomes of robotic pancreatectomy in patients with pancreatic cancer who receive adjuvant chemotherapy: A propensity score-matched retrospective c… Co-author DOI 10.1016/j.ijsu.2022.106801↗
  20. Postoperative hyperprogression disease of pancreatic ductal adenocarcinoma after curative resection: a retrospective cohort study. Co-author DOI 10.1186/s12885-022-09719-6↗
  21. Identification of EMT-related alternative splicing event of TMC7 to promote invasion and migration of pancreatic cancer. Co-author DOI 10.3389/fimmu.2022.1089008↗
  22. Worth it or not? Primary tumor resection for stage IV pancreatic cancer patients: A SEER-based analysis of 15,836 cases. Co-author DOI 10.1002/cam4.4147↗
  23. Oncological outcomes of robotic-assisted versus open pancreatoduodenectomy for pancreatic ductal adenocarcinoma: a propensity score-matched analysis. Co-author DOI 10.1007/s00464-020-07791-2↗
  24. Identification of copy number variation-driven molecular subtypes informative for prognosis and treatment in pancreatic adenocarcinoma of a Chinese cohort. Co-author DOI 10.1016/j.ebiom.2021.103716↗
  25. Original study: The rescue staging for pancreatic ductal adenocarcinoma with inadequate examined lymph nodes. Co-author DOI 10.1016/j.pan.2021.02.010↗
  26. Higher body mass index indicated better overall survival in pancreatic ductal adenocarcinoma patients: a real-world study of 2010 patients. Co-author DOI 10.1186/s12885-021-09056-0↗
  27. Preoperative plasma D-dimer independently predicts survival in patients with pancreatic ductal adenocarcinoma undergoing radical resection. Co-author DOI 10.1186/s12957-021-02281-8↗
  28. Preoperative Plasma D-Dimer Independently Predicts Survival in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Radical Resection Co-author DOI 10.21203/rs.3.rs-308863/v1↗
  29. Preoperative Score to Stratify Recurrence Risk After Curative Resection of Resectable Pancreatic Ductal Adenocarcinoma: A Retrospective Cohort Study Co-author DOI 10.21203/rs.3.rs-697919/v1↗
  30. Immunity-Related Gene Signature Identifies Subtypes Benefitting From Adjuvant Chemotherapy or Potentially Responding to PD1/PD-L1 Blockage in Pancreatic Cancer. Co-author DOI 10.3389/fcell.2021.682261↗
  31. A Novel c-MET-Targeting Antibody-Drug Conjugate for Pancreatic Cancer. Co-author DOI 10.3389/fonc.2021.634881↗
  32. Tumor copy number instability is a significant predictor for late recurrence after radical surgery of pancreatic ductal adenocarcinoma. First author DOI 10.1002/cam4.3425↗
  33. Surgical resection of metastatic pancreatic cancer: is it worth it?-a 15-year experience at a single Chinese center. Co-author DOI 10.21037/jgo.2020.03.02↗
  34. Serum tRNA-derived small RNAs as potential novel diagnostic biomarkers for Pancreatic Ductal Adenocarcinoma Co-author DOI 10.21203/rs.3.rs-63978/v1↗
  35. The Necessity of Dissection of No. 14 Lymph Nodes to Patients With Pancreatic Ductal Adenocarcinoma Based on the Embryonic Development of the Head of the Pancr… Co-author DOI 10.3389/fonc.2020.01343↗
  36. Should a standard lymphadenectomy include the No. 9 lymph nodes for body and tail pancreatic ductal adenocarcinoma? Co-author DOI 10.1016/j.pan.2019.03.005↗
  37. Comparison of Radical Antegrade Modular Pancreatosplenectomy with Standard Retrograde Pancreatosplenectomy for Left-Sided Pancreatic Cancer: A Meta-Analysis an… Co-author DOI 10.12659/msm.914540↗
  38. TRIANGLE operation for borderline resectable pancreatic cancer in total pancreatectomy. Co-author DOI 10.21037/tcr.2019.09.50↗
  39. A new enhanced recovery after surgery pathway for left-sided pancreatic cancer patients after distal pancreatectomy. Co-author DOI 10.21037/tcr.2019.10.26↗
  40. INPP4B As A Prognostic And Diagnostic Marker Regulates Cell Growth Of Pancreatic Cancer Via Activating AKT. Last author DOI 10.2147/ott.s223221↗
  41. Accuracy of Nodal Positivity in Inadequate Lymphadenectomy in Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma: A Population Study Using the US SEE… Co-author DOI 10.3389/fonc.2019.01386↗
  42. MicroRNA-300 promotes apoptosis and inhibits proliferation, migration, invasion and epithelial-mesenchymal transition via the Wnt/β-catenin signaling pathway b… Co-author DOI 10.1002/jcb.26270↗
  43. Melittin inhibits tumor growth and decreases resistance to gemcitabine by downregulating cholesterol pathway gene CLU in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2017.04.012↗
  44. TMEM45B promotes proliferation, invasion and migration and inhibits apoptosis in pancreatic cancer cells. Co-author DOI 10.1039/c6mb00203j↗
  45. mir-329 restricts tumor growth by targeting grb2 in pancreatic cancer. Co-author DOI 10.18632/oncotarget.7375↗
  46. NPM1 activates metabolic changes by inhibiting FBP1 while promoting the tumorigenicity of pancreatic cancer cells. Co-author DOI 10.18632/oncotarget.4167↗
  47. Outcomes of robotic surgery for pancreatic ductal adenocarcinoma. First author DOI 10.3978/j.issn.1000-9604.2015.05.05↗
  48. Snail recruits Ring1B to mediate transcriptional repression and cell migration in pancreatic cancer cells. Co-author DOI 10.1158/0008-5472.can-14-0181↗
  49. H2AK119Ub1 and H3K27Me3 in molecular staging for survival prediction of patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.18632/oncotarget.2126↗
  50. Clinical significance of RECK promoter methylation in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s13277-013-0903-z↗

Closest collaborators

The 25 strongest of 93 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Baiyong Shen · 42 shared papers, 2013–2026 · strength 5.44
  2. Chenghong Peng · 27 shared papers, 2013–2023 · strength 2.84
  3. Hao Chen · 18 shared papers, 2013–2022 · strength 1.55
  4. Haoda Chen · 9 shared papers, 2021–2023 · strength 1.52
  5. Yuanchi Weng · 11 shared papers, 2015–2023 · strength 1.47
  6. Weishen Wang · 10 shared papers, 2019–2024 · strength 1.46
  7. Jiabin Jin · 12 shared papers, 2013–2023 · strength 1.38
  8. Chenlei Wen · 10 shared papers, 2016–2026 · strength 1.32
  9. Ningzhen Fu · 8 shared papers, 2019–2023 · strength 1.18
  10. Shulin Zhao · 8 shared papers, 2019–2024 · strength 1.15
  11. Siyi Zou · 8 shared papers, 2019–2024 · strength 1.06
  12. Lingxi Jiang · 6 shared papers, 2020–2026 · strength 0.99
  13. Ziyun Shen · 6 shared papers, 2019–2023 · strength 0.98
  14. Dongfeng Cheng · 8 shared papers, 2018–2023 · strength 0.88
  15. Yu Jiang · 6 shared papers, 2019–2023 · strength 0.88
  16. Jun Zhang · 6 shared papers, 2020–2023 · strength 0.78
  17. Qian Zhan · 4 shared papers, 2021–2026 · strength 0.75
  18. Xiaomei Tang · 7 shared papers, 2016–2024 · strength 0.73
  19. Xiongxiong Lu · 8 shared papers, 2013–2023 · strength 0.73
  20. Baiyong Shen · 5 shared papers, 2016–2023 · strength 0.67
  21. Qian Zhan · 8 shared papers, 2013–2022 · strength 0.67
  22. Yiran Zhou · 4 shared papers, 2019–2023 · strength 0.64
  23. Kai Qin · 4 shared papers, 2021–2023 · strength 0.64
  24. Shuyu Zhai · 5 shared papers, 2019–2024 · strength 0.62
  25. Hao Chen · 4 shared papers, 2021–2024 · strength 0.59

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.